|
Facebook
Twitter
Linkedin
|
 |
 |
 |
 |
Healthcare Company News 
Accuray Incorporated Japan Treats First Extracranial Patients Using Cyberknife Radiosurgery
Accuray Incorporated Japan Treats First Extracranial Patients Using Cyberknife Radiosurgery
Japan Treats First Extracranial Patients Using Cyberknife Radiosurgery
Tuesday, 24 March 2009 04:40 | 
| Company News - Accuray Incorporated |
First Patients Treated in Yokohama, Japan Following Expanded Japanese Regulatory Approval
Accuray Incorporated , a global leader in the field of radiosurgery, announced that the first extracranial patients were treated in Japan using CyberKnife radiosurgery, following the System’s recently expanded regulatory approval.
The CyberKnife System (marketed in Japan as CyberKnife II) was previously approved in Japan to treat only intracranial, head and neck tumors. In June 2008 Accuray announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) had granted Shonin approval of the CyberKnife System for extracranial treatments, including tumors in the spine, lung, liver, pancreas and prostate. This regulatory approval and the upgraded capabilities dramatically expand the types of patients that can be treated with radiosurgery in the country.
“Having personally treated thousands of patients using CyberKnife radiosurgery, I was thrilled when the technology received Shonin approval for extracranial use,” said Kengo Sato, M.D., chief medical officer at Yokohama CyberKnife Center in Yokohama, Japan. “I have seen firsthand the System’s benefits in treating brain tumors and am very happy to be able to extend those benefits to our extracranial patients. We’re now treating patients who were previously considered untreatable and are very pleased with the results we’re seeing.”
“Japan remains the second largest installed base of CyberKnife Systems with more than 20 installed to date, so these extracranial treatments are just the beginning,” said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray. “These patients are the first of many to experience a convenient, comfortable and precise form of cancer care.”
About the CyberKnife Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray Incorporated
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 155 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, visit www.accuray.com.
Source: Accuray Incorporated
The CyberKnife System (marketed in Japan as CyberKnife II) was previously approved in Japan to treat only intracranial, head and neck tumors. In June 2008 Accuray announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) had granted Shonin approval of the CyberKnife System for extracranial treatments, including tumors in the spine, lung, liver, pancreas and prostate. This regulatory approval and the upgraded capabilities dramatically expand the types of patients that can be treated with radiosurgery in the country.
“Having personally treated thousands of patients using CyberKnife radiosurgery, I was thrilled when the technology received Shonin approval for extracranial use,” said Kengo Sato, M.D., chief medical officer at Yokohama CyberKnife Center in Yokohama, Japan. “I have seen firsthand the System’s benefits in treating brain tumors and am very happy to be able to extend those benefits to our extracranial patients. We’re now treating patients who were previously considered untreatable and are very pleased with the results we’re seeing.”
“Japan remains the second largest installed base of CyberKnife Systems with more than 20 installed to date, so these extracranial treatments are just the beginning,” said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray. “These patients are the first of many to experience a convenient, comfortable and precise form of cancer care.”
About the CyberKnife Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray Incorporated
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 155 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, visit www.accuray.com.
Source: Accuray Incorporated
